Biotech

All Articles

Neurocrine's offer to conserve schizophrenia possibility falls short

.Neurocrine Biosciences' mental illness plan pivot has neglected. The biotech was not able to reprod...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has brought in an overdue access to the radioligand party, paying one hundred million euros ...

F 2G rears $100M for second attempt to acquire brand-new antifungal to market

.After F2G's very first attempt to receive a brand-new training class of antifungal to market was hi...

Moderna targets $1.1 B in R&ampD investing cuts, falls 5 courses amid success tensions

.Moderna has sworn to cut R&ampD spending through $1.1 billion by 2027. The decision to retract the ...

Sanofi's $80M bank on Pivot dystrophy medication ends in stage 3 go under

.Only four months after Sanofi bet $80 thousand in beforehand cash on Pivot Therapeutics' losmapimod...

Oncternal equity sinks 60% amidst discharges, test terminations

.Cancer business Oncternal Therapies is actually folding all its own professional trials as well as ...

Roche is keeping out hopes that its injectable weight problems possibility can ultimately demonstrate 25% weight management in late-stage test

.Roche is actually holding out hopes that its injectable weight problems possibility could ultimatel...

Novo Nordisk hails 'exceptional' weight loss lead for dual-acting oral medication in very early test

.Novo Nordisk has lifted the top on a period 1 test of its own oral amylin as well as GLP-1 receptor...

AbbVie takes legal action against BeiGene over blood cancer medicine secret method

.Merely a handful of short weeks after succeeding an FDA Fast lane tag for its own investigational B...

Lilly supplies one-two blow along with 2nd tranche of positive data on regular the hormone insulin applicant

.Soon after a good data decline for Eli Lilly's efsitora alfa, the Indianapolis-based provider is on...